This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
CORE-001
CS-003
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Decipher Genomic Classifier
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
PSMA-Targeted Therapy
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
Masofaniten (EPI-7386)
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
WCET 2024
SUPS 2024
BCAN TT 2024
SNMMI 2024
ASCO 2024
AUA 2024
All Conferences
View All
PCF
UroToday Home
Conference Highlights
ASCO 2024
ASCO 2024 Bladder Cancer
Conferences
ASCO 2024
Prostate Cancer
Bladder Cancer
Kidney Cancer
Testicular and Penile Cancer
Upper Tract Urothelial Carcinoma
Press Releases
ASCO 2024 Bladder Cancer
Viewing 181-200 of 344 articles
AUA 2017:Non-Muscle Invasive Bladder Cancer Guidelines
AUA 2017: High Risk Non-Muscle Invasive Bladder Cancer
AUA 2017: What is Best Systemic Therapy for Metastatic/Invasive Bladder Cancer?
AUA 2017: What is the Best Imaging and What Will We Be Using in the Future: Cystoscopy and Cross-Sectional Imaging?
AUA 2017: Beyond Cytology: What is the Urinary Marker We Should Use Now and What Will Be the Best in the Future?
AUA 2017: Best Urothelial Cancer papers from 2016
AUA 2017: How I Screen - Panel
AUA 2017: Neoadjuvant sorafenib, gemcitabine, and cisplatin (SGC) for muscle-invasive urothelial bladder cancer (MIUBC): final results and translational findings of an open-label, single-arm, phase 2 study
AUA 2017: Development and external validation of a novel 12-gene signature on muscle-invasive bladder cancer for prediction of overall survival: linkage to data from The Cancer Genome Atlas
AUA 2017: Molecular subtypes of muscle invasive bladder cancer are related to benefit from neoadjuvant chemotherapy
AUA 2017: Genome Drivers of Response to Existing and Emerging Therapies in Bladder Cancer
AUA 2017: Creating an Institution-Wide Systems Biology Initiative
AUA 2017: Studying Niche Populations: Neuroendocrine Prostate Cancers
AUA 2017: Leveraging the Power of Ultra-Deep Sequencing (When Deep Sequencing Fails)
AUA 2017: Opportunities and Challenges Associated with Big Data
AUA 2017: Prospective Study Of Biopsy Decipher Scores In Potential Candidates For Active Surveillance
AUA 2017: Multiparametric-MRI Prior To Repeat Biopsy For Active Surveillance Can Identify Men With High-risk Prostate Cancer
AUA 2017: Concordance Between Physician-documented Versus Patient-reported Comorbidities In Prostate Cancer: Validation Of A Novel Informatics Tool
AUA 2017: Worldwide Variation In Determinants For Inclusion And Follow-up In Active Surveillance For Low-risk Prostate Cancer: Results Of The Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Initiative
AUA 2017: Association Between Germline Genetic Variation And Progression In Men With Low-risk Prostate Cancer On Active Surveillance
5
6
7
8
9
10
11
12
13
14
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free